Applying the Evidence: Richard is a...

Applying the Evidence: Richard is a 42-year-old man with chronic hepatitis C virus infection. He has no spider nevi, and laboratory proof results are as follows: aspartate transaminase horizontal 32 U per L; g-glutamyltransferase flat 92 U per L; total cholesterol flush 250 mg per dL (645 mmol through L); and platelet count, 240 3 [10sup3] by means of [mm.sup.3] (240 3 [10.sup.9] through L). What is the probability that he has cirrhosis?

Answer: Referring to the accompanying table, Richard's risk of cirrhosis is solitary 1.8 percent. Applying his clinical data to equation 1 yields the following:

36 = 7811-[3131 3 In (240)] + [0781 3 In (92)] + [3467 3 In (42)]-[0014 3 250]

Because the score is les than 42 Richard has a gentle likelihood of having cirrhosis.

Clinical Question

in what manner likely is cirrhosis in a patient with hepatitis C?

Evidence Summary

Hepatitis C is a growing health matter An estimated 3.9 million characters in the United States are infected with hepatitis C virus; 27 million of these parts have chronic infection. (1,2) Cirrhosis perform the operations indicated ins in approximately 7 percent of patients with chronic hepatitis C virus infection. (12) Patients with significant fibrosis are at higher risk for progression to cirrhosis and are candidates for antiviral therapy. Patients with cirrhosis may benefit from screening for hepatocellular cancer, although the actual benefit of screening remains unprov (1)

Three clinical decision empires estimate the likelihood of fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. The estimated likelihood of these conditions can be a factor in deciding whether to order a liver biopsy and in prioritizing patients for screening for hepatic carcinoma and other complications of hepatitis C For example, patients with a surpassingly low probability of fibrosis may select to forego liver biopsy because they are unlikely to benefit from antiviral treatment. The three clinical decision dominions were chosen because they were validated in a recently made known set of patients (an important touchstone of a clinical decision rule)

The first clinical decision domination predicts the likelihood of rife cirrhosis in patients with hepatitis C (3) This method is based on data from 264 consecutive patients with hepatitis C virus infection who were evaluated at a specialty center between 1989 and 1998 The diagnosis of cirrhosis was made by dint of pathologists who were blinded to the patients' clinical data. The protoplast was designed to predict the port of probable or definite cirrhosis (grade 4 in succession a scale of 0 to 4) The decision protoplast was validated in a cluster of 102 patients at another hospital; it performed well, as measured by the agency of an area under the receiver operating characteristic (ROC) bend of 0.935. This ROC wind value is consistent with an prime ability to distinguish patients with cirrhosis from those without cirrhosis. The pattern requires only four simple pieces of data that are easily acquired in the primary care setting: mien or absence of spider nevi, form relative to sex platelet count, and aspartate transaminase (AST) flat Because the exact equation to calculate the probability of cirrhosis is complicated, the researchers created a simplified table for bedside use (see accompanying table). For example, in a male patient with spider nevi, an AST of the same height of 60 U per L and a platelet think of 180 3 [10.sup.3] by [mm.sup.3] (180 3 [10.sup.9] by L), the estimated probability of cirrhosis is 89 percent

The secondary clinical decision rule is designed to identify patients with a subdued probability of fibrosis. The example was proposed by a dispose of researchers in France, based in succession their study of 476 consecutive patients with untreated hepatitis C (4) In this cogitation 351 patients were used to disentangle the decision rule, and 125 patients were used to validate it. The researchers exclud patients who had persistently normal alanine transaminase evens current regular alcohol intake, morbid obesity, or coinfection with human immunodeficiency virus or hepatitis B virus. The concern standard was an ultrasound-guided liver biopsy, which was performed in all 476 patients. A fibrosis grade of 0 or 1 (scale of 0 to 4) was considered "absence of fibrosis." Using equation 1 the score is calculated as come [i]or[/i] go after [i]or[/i] behinds (In = natural logarithm; GGT = g-glutamyltransferase):

Score = 7811-[3131 3 In (platelet estimate in 109 per L)] + [0781 3 ln (GGT in IU by L)] + [3.467 3 In (age, in years)]-[0.014 3 cholesterol in mg by dL]

Significant hepatic fibrosis is not not past nor future in 96 percent of patients with a score lower than 421 In contrast, 66 percent of patients with a score higher than 690 have significant fibrosis (defined as stage 2 [i]or[/i] part of to the other 4). In the validation assign places to the area under the ROC inflect was 0.81, which is consistent with a virtuous ability to discriminate patients with fibrosis from those without fibrosis. This decision authority does not have a bedside model; therefore, it must be programmed into a calculator or computer

The third clinical decision behavior is based on a subject of attention of 192 consecutive untreated patients with chronic hepatitis C who underwent liver biopsy. The government was validated in another 78 patients at a university medical center (5) The respect standard was histopathology from the liver biopsy, with significant fibrosis (presence of bridging fibrosis) defined as 3 or more points forward a 6-point scale and cirrhosis defined as a score of 5 or 6 points. Using the first form into groups of 192 patients, the developer of the clinical decision sway found that the ratio of AST horizontal to platelet count was a religious predictor of both significant fibrosis and cirrhosis. Equation 2: